Cholera-endemic Eastern India has played an important role in the development of oral cholera vaccines (OCV) through conduct of pivotal trials in Kolkata which led to the registration of the first low-cost bivalent killed whole cell OCV in India in 2009, and subsequent prequalification by the World Health Organization prequalification in 2011. Odisha hosted an influential early demonstration project for use of the vaccine in a high-risk population and provided data and lessons that were crucial input in the Vaccine Investment Strategy developed by Gavi, the Vaccine Alliance in 2013. With Gavi's decision to finance an OCV stockpile, the demand for OCV surged and vaccine has been deployed with great success worldwide in areas of need in response to outbreaks and disasters, most notably in Africa. However, although India is considered one of the highest burden countries, no further use of OCV has occurred since the demonstration project in Odisha in 2011. In this paper we will summarize the important contributions of India to the development and use of OCV and discuss the possible barriers to OCV introduction as a public health tool to control cholera.

中文翻译：

---

印度OCV的历史以及程序引入的障碍。

通过在加尔各答进行的关键试验，霍乱地方性印度东部在口服霍乱疫苗（OCV）的开发中发挥了重要作用，该试验导致印度在2009年注册了首个低成本的二价杀死全价被杀死的全细胞OCV，随后由世界卫生组织（WHO）在2011年进行资格预审。奥里萨邦（Odisha）主持了一个有影响力的早期示范项目，在高风险人群中使用该疫苗，并提供了数据和经验教训，这些数据和经验教训对加维疫苗联盟（Gavi）制定的疫苗投资策略至关重要。 2013年。随着Gavi决定为OCV储存提供资金的决定，对OCV的需求激增，疫苗已在全球应对疫情和灾难的需求领域获得了巨大成功，尤其是在非洲。然而，